| Cover and Content | |
| 1-4 |
| Analysis of the cost-effectiveness of three-component therapies with daratumumab for the treatment of patients with recurrent refractory multiple myeloma | |
| T. Vekov, H. Lebanova, N. Veleva, V. Belcheva, J. Kolev, M Vlahova | 5-12 |
| Analysis of marketing authorization procedures with negative opinion 2020-2021 – how EMA handled challenges in drug therapy during Covid-19 pandemic | |
| Violeta Getova, Ilko Getov | 13-19 |
| Role of the list of standard terms in the European Pharmacopoeia for the establishment of the different existing pharmaceutical forms | |
| Rostislav Atanasov, Valentina Belcheva, Evgeni Grigorov | 20-25 |
| Peptide drug delivery: oral approaches | |
| Krum Kafedjiiski | 26-32 |
| Current pharmacotherapy of uterine leiomyomas | |
| Vesela Karamisheva | 33-38 |
| Antibiotic resistance - a new challenge following the COVID-19 pandemic | |
| Stefan Balkanski | 39-45 |
| Do sacubitril/valsartan affect neurocognitive function? | |
| Ralitsa Pancheva | 46-50 |
| Diabetes mellitus and hyperglycemia - pathogenesis: focus on SGLT inhibitors | |
| Hristina Nocheva, Mariana Yoncheva, Valentina Belcheva, Evgeni Grigorov | 51-61 |
| Promoting clinical pharmacy services through advanced medication review in the emergency department | |
| Ana de Lorenzo-Pinto, Raquel García-Sánchez, Ana Herranz, Iria Miguens, María Sanjurjo-Sáez | 62-69 |
| Prevalence of drug interactions in hospitalised elderly patients: a systematic review | |
| Luciana Mello de Oliveira, Juliana do Amaral Carneiro Diel, Alessandra Nunes, Tatiane da Silva Dal Pizzol | 70-80 |